Public Employees Retirement System of Ohio Purchases New Position in Globus Medical, Inc. $GMED

Public Employees Retirement System of Ohio purchased a new position in Globus Medical, Inc. (NYSE:GMED) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 100,510 shares of the medical device company’s stock, valued at approximately $7,941,000.

Several other large investors also recently added to or reduced their stakes in GMED. Elevation Wealth Partners LLC raised its position in Globus Medical by 2,178.6% during the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 305 shares during the period. SBI Securities Co. Ltd. boosted its holdings in shares of Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the period. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Finally, Larson Financial Group LLC increased its position in shares of Globus Medical by 83.4% during the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 242 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Globus Medical Stock Performance

GMED opened at $80.32 on Wednesday. The stock’s 50 day moving average price is $81.18 and its 200-day moving average price is $84.49. Globus Medical, Inc. has a one year low of $54.15 and a one year high of $101.40. The stock has a market cap of $10.78 billion, a price-to-earnings ratio of 20.54, a P/E/G ratio of 1.31 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The company had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.Globus Medical’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, analysts predict that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Truist Financial cut their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. BMO Capital Markets initiated coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 target price on the stock. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Stifel Nicolaus dropped their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research note on Wednesday, July 8th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.77.

Insider Buying and Selling at Globus Medical

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 18.38% of the stock is currently owned by company insiders.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.